Fig. 6: Capability of siRNA/Ap-CS to knocked down Plk1 mRNA and PLK1 protein expression within MCF-7 cells. | Nature Communications

Fig. 6: Capability of siRNA/Ap-CS to knocked down Plk1 mRNA and PLK1 protein expression within MCF-7 cells.

From: Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs

Fig. 6

The siRNA-targeting Plk1 is abbreviated as siPlk1. After being treated with siPlk1 in different formulations, Plk1 mRNA levels were measured by qPCR (a), PLK1 protein expression was analyzed by western blotting (n = 3) (b) and cell viability was test by CCK-8 kit (c). The western blot analysis was performed three times independently with similar results. d Cell viability of MCF-7 cells treated with different amounts of siRNA/Ap-CS. The concentration of siRNA in siRNA/Ap-CS ranges from 0 to 1.82 μM, where the value of 0 indicates that Ap-CS formulation without siRNA was used under identical conditions. The error bar in a, c and d represents the standard deviation (SD), and the measured data are expressed as the means ± SD (n = 3). *P < 0.05, **P < 0.01, two-tailed unpaired t test.

Back to article page